Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03069911 · ClinicalTrials.gov registry record · Phase 1
Trial of OnabotulinumtoxinA for Depression in Parkinson Disease
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03069911: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT03069911 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03069911, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of onabotulinumtoxinA (BOTOX®) in the treatment of depression associated with Idiopathic Parkinson Disease in adults. As a Randomized Controlled Trial, half of the participants will receive onabotulinumtoxinA injections and half will receive a placebo saline solution.
Interventions
- BIOLOGICAL OnabotulinumtoxinA
- BIOLOGICAL Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03069911
The ClinicalTrials.gov registry entry for NCT03069911 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OnabotulinumtoxinA is the first listed.
NCT03069911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03069911 about?
NCT03069911 is a clinical study titled "Trial of OnabotulinumtoxinA for Depression in Parkinson Disease". This study evaluates the efficacy of onabotulinumtoxinA (BOTOX®) in the treatment of depression associated with Idiopathic Parkinson Disease in adults. As a Randomized Controlled Trial, half of the participants will receive onabotulinumtoxinA injections and half will receive a placebo saline solutio...
What is the current status of trial NCT03069911?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-11-01. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT03069911?
The interventions under investigation include: OnabotulinumtoxinA (BIOLOGICAL), Control (BIOLOGICAL).
Who is sponsoring clinical trial NCT03069911?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.